Stress, the body's natural response to different types of challenges and daily problems, is an inherently harmless state ...

The gonadotropin hormone receptors, including the follicle-stimulating hormone receptor (FSHR) and the luteinizing hormone/choriogonadotropin receptor (LH/CGR), serve as integral mediators of ...

Hormone therapies have played a major role in improving survival for patients with ER+ breast cancer [1]. By blocking or reducing estrogen’s impact, these treatments slow the cancer’s growth and help ...

The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...

Progesterone Receptor Positive (PR+) breast cancer is a distinct biological subtype of hormone receptor positive breast cancer. This type of cancer grows in response to progesterone, a hormone that is ...

FDA removes black box warnings for most MHT products, reflecting evidence that breast cancer risk varies by formulation, ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

The role of oestrogen receptor beta (ERβ) in breast cancer continues to be a subject of considerable scientific enquiry. Traditionally overshadowed by its counterpart, ERα, ERβ is now understood to be ...

Not only do women get more migraines than men, but a new study shows they also experience them for a longer duration.

By Dennis Thompson HealthDay ReporterTUESDAY, Jan. 6, 2026 (HealthDay News) — A drug that mimics the female hormone ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...